Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers

Cancer Treatment Reviews

Volumn 39, Issue 3, 2013, Pages 230-240

  Castellano, Daniel ^a   Ravaud, Alain ^b   Schmidinger, Manuela ^c   De Velasco, Guillermo ^a   Vazquez, Federico ^d  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b INSERM   (France)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Biomarkers; Dosing; Metastatic renal cell carcinoma; Side effect management; Sunitinib; Therapy management; Treatment duration

Indexed keywords

ALPHA INTERFERON; AMLODIPINE; BEVACIZUMAB; BIOLOGICAL MARKER; CANDESARTAN; CAPTOPRIL; CLARITHROMYCIN; ENALAPRIL; ERYTHROMYCIN; FELODIPINE; FOSINOPRIL; IRBESARTAN; ITRACONAZOLE; KETOCONAZOLE; LABETALOL; LISINOPRIL; LOSARTAN; NIFEDIPINE; OLMESARTAN; PAZOPANIB; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; RITONAVIR; SUNITINIB; TELMISARTAN; TEMSIROLIMUS; UNINDEXED DRUG; VALSARTAN;

ANEMIA; ANOREXIA; ASTHENIA; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPEPSIA; EPISTAXIS; FATIGUE; GENETIC VARIABILITY; GENOTYPE; GRAPEFRUIT JUICE; HAIR COLOR; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; HYPOTHYROIDISM; KIDNEY METASTASIS; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PATIENT EDUCATION; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROGNOSIS; PYRROLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84873986363     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.04.009     Document Type: Review

References (66)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
2. Rabinovitch R.A., Zelefsky M.J., Gaynor J.J., Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994, 12:206-212.
3. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al., editors SEER cancer statistics review, 1975-2005. National Cancer Institute. ; 2008.
4. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
5. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
6. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
7. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
8. Motzer R.J., Hutson T.E., Tomczak P., Dror Michaelson M., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
9. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Ou S.S., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428.
10. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
11. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
12. Rini B.I., Escudier B., Tomczak P., Kaprin A., Hutson T.E., Szczylik C., et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 2011, 29(Suppl. l). [abstract 4503].
13. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;CD001425.
14. Escudier B., Bellmunt J., Négrier S., Bajetta E., Melichar B., Bracarda S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28:2144-2150.
15. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Archer L., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
16. Sternberg C, Hawkins RE, Szczylik C, Davis I, Wagstaff J, McCann L, et al. Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma: final overall survival results. Ann Oncol 2010;21:viii10 [abstract LBA22].
17. Ljungberg B., Cowan N., Hanbury D.C., Hora M., Kuczyk M.A., Merseburger A.S., et al. Guidelines on renal cell carcinoma. Eur Urol 2010, http://www.uroweb.org/?id=218&gid=4.
18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v.2. ; 2011.
19. Gore M.E., Szczylik C., Porta C., Bracarda S., Bjarnason G.A., Oudard S., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-763.
20. Houk B.E., Bello C.L., Poland B., Rosen L.S., Demetri G.D., Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371.
21. Pfizer Inc. SUTENT, Summary of product characteristics. ; July 2010.
22. Porta C, Szczylik C, Bracarda S, Hawkins R, Oudard S, Lee SH, et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. In: 44th Annual Meeting of the American Society of Clinical Oncology, 30 May-3 June 2008, Chicago, IL.
23. Bhojani N., Jeldres C., Patard J.J., Perrotte P., Suardi N., Hutterer G., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008, 53:917-930.
24. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
25. Negrier S., Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl 2007, 5:12-19.
26. du Bois A., Rochon J., Pfisterer J., Hoskins W.J. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 2009, 112:422-436.
27. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006, 98:172-180.
28. Giede K.C., Kieser K., Dodge J., Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005, 99:447-461.
29. Vernooij F., Heintz P., Witteveen E., Van der G.Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 2007, 105:801-812.
30. Roigas J. Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. Eur Urol Suppl 2008, 7:593-600.
31. Motzer R.J., Hutson T.E., Olsen M.R., Hudes G.R., Burke J.M., Edenfield W.J., et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012, [Epub ahead of print].
32. Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 2009, 20(Suppl. 1):i7-i12.
33. Kollmannsberger C., Soulieres D., Wong R., Scalera A., Gaspo R., Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007, 1(Suppl.):S41-S54.
34. Lee S, Chung HC, Mainwaring P, Ng C, Chang JWC, Kwong P, et al. An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer 2009;7(Suppl.) [abstract 428].
35. Hong M.H., Kim H.S., Kim C., Ahn J.R., Chon H.J., Shin S.J., et al. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 2009, 41:67-72.
36. van Erp N.P., Eechoute K., van der Veldt A.A., Haanen J.B., Reyners A.K., Mathijssen R.H., et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009, 27:4406-4412.
37. Garcia-Donas J., Esteban E., Leandro-Garcia J., Castellano D.E., Del Alba A.G., Climent M., et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011, 12(12):1143-1150.
38. Wolter P., Stefan C., Decallonne B., Dumez H., Bex M., Carmeliet P., et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008, 99:448-454.
39. Lacouture M.E., Wu S., Robert C., Atkins M.B., Kong H.H., Guitart J., et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008, 13:1001-1011.
40. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
41. Sica D.A. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006, 24:1329-1331.
42. Bhargava P. VEGF kinase inhibitors: how do they cause hypertension?. Am J Physiol Regul Integr Comp Physiol 2009, 297:R1-R5.
43. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6:465-477.
44. Rini B.I., Schiller J.H., Fruehauf J.P., Cohen E.E., Tarazi J.C., Rosbrook B., et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011, 17:3841-3849.
45. Harzstark A, Halabi S, Stadler WM, Vaena D, Atkins JN, Picus J, et al. Hypertension is associated with clinical outcome for patients (pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90296. In: The American Society of Clinical Oncology Genitourinary Cancers symposium, 5-7 March 2010, San Francisco, CA, [abstract 351].
46. Rini B.I., Cohen D.P., Lu D.R., Chen I., Hariharan S., Gore M.E., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
47. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
48. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
49. Vakkalanka B.K., Elson P., Wood L., Dreicer R., Garcia J.A., Bukowski R.M., et al. Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC). J Clin Oncol 2008, 26(Suppl.). [abstract 16045].
50. Porta C., Szczylik C., Bracarda S., Hawkins R., Bjarnason G.A., Oudardet S., et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2008, 26:5114.
51. Richards C.J., Je Y., Schutz F.A.B., Choueiri T.K. Meta-analysis of randomized control trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012, 30(Suppl. 5). [abstract 349].
52. Joly F. Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?. Bull Cancer 2011 Oct, 98:1071-1081. [in French].
53. Ayllon J., Beuselinck B., Morel A., Barrascout E., Medioni J., Scotte F., et al. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma. Cancer Invest 2011, 29:282-285.
54. Maitland M.L., Bakris G.L., Black H.R., Chen H.X., Durand J.B., Elliott W.J., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010, 102:596-604.
55. Schmidinger M., Arnold D., Szczylik C., Wagstaff J., Ravaud A. Optimising the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 2010, 28:856-864.
56. Grunwald V., Kalanovic D., Merseburger A.S. Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. World J Urol 2010, 28:343-351.
57. Schwandt A., Wood L.S., Rini B., Dreicer R. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther 2009, 2:51-61.
58. Rini B.I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99:81-83.
59. Baskin H.J., Cobin R.H., Duick D.S., Gharib H., Guttler R.B., Kaplan M.M., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002, 8:457-469.
60. Kollmannsberger C., Bjarnason G., Burnett P., Creel P.A., Davis M., Dawson N., et al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 2011, 16:543-553.
61. Hercbergs A.A., Goyal L.K., Suh J.H., Lee S., Reddy C.A., Cohen B.H., et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 2003, 23:617-626.
62. Nelson M., Hercbergs A., Rybicki L., Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006, 132:1041-1046.
63. Wolter P, Stephan C, Decallonne B, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). In: the 44th Annual Meeting of the American Society of Clinical Oncology, 30 May-3 June 2008, Chicago, IL, [abstract 5126].
64. Schmidinger M., Vogl U.M., Bojic M., Lamm W., Heinzl H., Haitel A., et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?. Cancer 2010, 117:534-544.
65. Robert C., Soria J.C., Spatz A., Le Cesne A., Malka D., Pautier P., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005, 6:491-500.
66. Michaelson M.D., Cohen D.P., Li S., Motzer R.J., Escudier B., Barrios C.H., et al. Hand-foot syndrome as a potential biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Clin Oncol 2011, 29(Suppl. 7). [abstract 320].